|
Description: A safe and effective vaccine for dengue virus is needed by the U.S. Armed Forces. Dengue causes a temporarily incapacitating illness in troops operating in the tropics. It has dramatic epidemic potential, and caused attack rates as high as 80% during World War II. In the Somalia campaign, dengue was the infection most often confused with malaria (the symptoms are very similar), and dengue was the most common infectious cause of hospital admission during the recent U.S. intervention in Haiti. Control of mosquitoes that transmit dengue is not practical in combat or in areas where there is civil unrest. A vaccine is needed to protect troops from dengue and to prevent units from suffering mission aborting high attack rates. Traditional technologies using live-attenuated dengue vaccines and purified-inactivated protein vaccines have not produced an acceptable vaccine. No current vaccine candidate can reliably prevent infection by all 4 serotypes of dengue while producing an acceptable side effect profile. This effort will use the novel recombinant adenovirus vector technologies to develop a vaccine for dengue. An effective dengue vaccine is also highly beneficial to civilian population in endemic areas, and people traveling to endemic areas.
|
|
| |
| Gen Phar |
$1,941 |
|
For-Profit |
Mt. Pleasant,
SC
|
|
|
Citation
|
|
Source:
Appropriations Report Language - Conference
|
|
Reference:
108-622
|
|
Location:
Line 130, Page 303
|
Citation Excerpt: Multivalent Dengue Vaccine Program
|
|
